ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Haematology · Lancet Haematol · 2025-12-06

Post hoc analysis of 1766 patients with cancer-associated VTE on extended apixaban: anaemia and/or thrombocytopenia (SHR 1.93), age 75 or older (1.51), PE as index event (1.47) and male sex (1.38) predicted clinically relevant bleeding, regardless of dose.

Secondary analysisn = 1,766
Mahé et al. Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.